The changing therapeutic landscape of castration-resistant prostate cancer (original) (raw)

• Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
  Article PubMed Google Scholar
• Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765–781 (2010).
  Article CAS PubMed Google Scholar
• Pienta, K. J. & Bradley, D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 12, 1665–1671 (2006).
  Article CAS PubMed Google Scholar
• Yap, T. A., Carden, C. P., Attard, G. & de Bono, J. S. Targeting CYP17: established and novel approaches in prostate cancer. Curr. Opin. Pharmacol. 8, 449–457 (2008).
  Article CAS PubMed Google Scholar
• [No authors listed]. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355, 1491–1498 (2000).
• Figg, W. D. et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am. J. Med. 98, 412–414 (1995).
  Article CAS PubMed Google Scholar
• Nishimura, K. et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89, 2570–2576 (2000).
  Article CAS PubMed Google Scholar
• Small, E. J. et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025–1033 (2004).
  Article CAS PubMed Google Scholar
• Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
  Article CAS PubMed Google Scholar
• Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).
  Article CAS PubMed Google Scholar
• Attard, G. et al. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br. J. Cancer 95, 767–774 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Y., Clegg, N. J. & Scher, H. I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 10, 981–991 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Yamaoka, M., Hara, T. & Kusaka, M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin. Cancer Res. 16, 4319–4324 (2010).
  Article CAS PubMed Google Scholar
• Bruno, R. D. & Njar, V. C. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg. Med. Chem. 15, 5047–5060 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Labrie, C., Cusan, L., Plante, M., Lapointe, S. & Labrie, F. Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer. J. Steroid Biochem. 28, 379–384 (1987).
  Article CAS PubMed Google Scholar
• Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653–4657 (2005).
  Article CAS PubMed Google Scholar
• He, B. et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 16, 425–438 (2004).
  Article CAS PubMed Google Scholar
• Taplin, M. E. et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 101, 1084–1089 (2008).
  Article CAS PubMed Google Scholar
• Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).
  Article CAS PubMed Google Scholar
• Harris, W. P., Mostaghel, E. A., Nelson, P. S. & Montgomery, B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 6, 76–85 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Venkitaraman, R. et al. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int. 101, 440–443 (2008).
  CAS PubMed Google Scholar
• Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756–1764 (1996).
  Article CAS PubMed Google Scholar
• Kantoff, P. W. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17, 2506–2513 (1999).
  Article CAS PubMed Google Scholar
• Nishimura, K. et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl Cancer Inst. 93, 1739–1746 (2001).
  Article CAS PubMed Google Scholar
• Morioka, M. et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol. Int. 68, 10–15 (2002).
  Article CAS PubMed Google Scholar
• Saika, T. et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int. J. Urol. 8, 290–294 (2001).
  Article CAS PubMed Google Scholar
• Berry, W., Dakhil, S., Modiano, M., Gregurich, M. & Asmar, L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol. 168, 2439–2443 (2002).
  Article CAS PubMed Google Scholar
• Fossa, S. D. et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur. Urol. 52, 1691–1698 (2007).
  Article PubMed CAS Google Scholar
• Chang, C. Y., Walther, P. J. & McDonnell, D. P. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res. 61, 8712–8717 (2001).
  CAS PubMed Google Scholar
• Fousteris, M. A. et al. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth. Bioorg. Med. Chem. 18, 6960–6969 (2010).
  Article CAS PubMed Google Scholar
• Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375, 1437–1446 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2011).
• Jarman, M., Barrie, S. E. & Llera, J. M. The 16, 17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl) androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J. Med. Chem. 41, 5375–5381 (1998).
  Article CAS PubMed Google Scholar
• Rowlands, M. G. et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17, 20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J. Med. Chem. 38, 4191–4197 (1995).
  Article CAS PubMed Google Scholar
• Potter, G. A., Barrie, S. E., Jarman, M. & Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471 (1995).
  Article CAS PubMed Google Scholar
• Barrie, S. E. et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17–20 lyase). J. Steroid Biochem. Mol. Biol. 50, 267–273 (1994).
  Article CAS PubMed Google Scholar
• Bianchini, D., Zivi, A., Sandhu, S. & de Bono, J. S. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Expert Opin. Investig. Drugs 19, 1487–1502 (2010).
  Article CAS PubMed Google Scholar
• O'Donnell, A. et al. Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90, 2317–2325 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563–4571 (2008).
  Article CAS PubMed Google Scholar
• Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742–3748 (2009).
  Article CAS PubMed Google Scholar
• Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489–1495 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ryan, C. J. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28, 1481–1488 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496–1501 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• FDA. Abiraterone Acetate [online], (2011).
• Dreicer, R. et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3084 (2010).
  Article Google Scholar
• Handratta, V. D. et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972–2984 (2005).
  Article CAS PubMed Google Scholar
• Tokai Pharmaceuticals. Tokai pharmaceuticals initiates ARMOR clinical development program for TOK-001; first ever multi-target investigational drug for prostate cancer [online], (2009).
• Berthold, D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242–245 (2008).
  Article CAS PubMed Google Scholar
• Scher, H. I. et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial [abstract]. J. Clin. Oncol. 28, (15 Suppl.), a4509 (2010).
  Article Google Scholar
• Small, E. et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. Genitourinary Cancers Symp. a7 (2009).
• Kelly, W. K. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 [abstract]. J. Clin. Oncol. 28 (18 Suppl.), LBA4511 (2010).
  Article Google Scholar
• Franke, R. M., Carducci, M. A., Rudek, M. A., Baker, S. D. & Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J. Clin. Oncol. 28, 4562–4567 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ansari, J. et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol. Rep. 20, 891–896 (2008).
  CAS PubMed Google Scholar
• Eymard, J. C. et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 106, 974–978 (2010).
  Article CAS PubMed Google Scholar
• Bracarda, S., Logothetis, C., Sternberg, C. N. & Oudard, S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int. 107 (Suppl. 2), 13–20 (2011).
  Article CAS PubMed Google Scholar
• Sartor, A. O. et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial [abstract]. J. Clin. Oncol. 26, a5003 (2008).
  Article Google Scholar
• Kelland, L. R. et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. 53, 2581–2586 (1993).
  CAS PubMed Google Scholar
• Yap, T. A., Sandhu, S. K., Carden, C. P. & de Bono, J. S. Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 61, 31–49 (2011).
  Article PubMed Google Scholar
• de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
  Article CAS PubMed Google Scholar
• Attard, G., Greystoke, A., Kaye, S. & De Bono, J. Update on tubulin-binding agents. Pathol. Biol. (Paris) 54, 72–84 (2006).
  Article CAS Google Scholar
• Aller, A. W., Kraus, L. A. & Bissery, M.-C. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract 1923]. Proc. Am. Assoc. Cancer Res. 41, 303 (2000).
  Google Scholar
• Bissery, M.-C. et al. Preclinical evaluation of TXD258, a new taxoid [abstract 1364]. Proc. Am. Assoc. Cancer Res. 41, 214 (2000).
  Google Scholar
• Mita, A. C. et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15, 723–730 (2009).
  Article CAS PubMed Google Scholar
• Pivot, X. et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19, 1547–1552 (2008).
  Article CAS PubMed Google Scholar
• FDA. Cabazitaxel [online], (2010).
• Rosenberg, J. E. et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110, 556–563 (2007).
  Article CAS PubMed Google Scholar
• Beardsley, E. K. et al. A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel [abstract 5139]. J. Clin. Oncol. 27 (15 Suppl.), a5139 (2009).
  Google Scholar
• Ribas, A. & Flaherty, K. T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426–433 (2011).
  Article CAS PubMed Google Scholar
• Sanda, M. G. et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151, 622–628 (1994).
  Article CAS PubMed Google Scholar
• Wang, X. et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224–1235 (2005).
  Article CAS PubMed Google Scholar
• Drake, C. G. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10, 580–93 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Di Lorenzo, G., Buonerba, C. & Kantoff, P. W. Immunotherapy for the treatment of prostate cancer. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2011.72.
• Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).
  Article CAS PubMed Google Scholar
• Higano, C. S. et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670–3679 (2009).
  Article CAS PubMed Google Scholar
• Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
  Article CAS PubMed Google Scholar
• Higano, C. S. et al. Sipuleucel-T. Nat. Rev. Drug Discov. 9, 513–514 (2010).
  Article CAS PubMed Google Scholar
• Nilsson, S., O' Bryan-Tear, C. G., Bolstad, B., Lokna, A. & Parker, C. C. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223 [abstract]. J. Clin. Oncol. 29 (Suppl.), a4620 (2011).
  Article Google Scholar
• Bayer. Alpharadin significantly improves overall survival in phase III trial in patients with castration-resistant prostate cancer that has spread to the bone [online], (2011).
• James, N. D. et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int. 106, 966–973 (2010).
  Article CAS PubMed Google Scholar
• Nelson, J. B. et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113, 2478–2487 (2008).
  Article CAS PubMed Google Scholar
• Carducci, M. A. et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110, 1959–1966 (2007).
  Article CAS PubMed Google Scholar
• Kummar, S., Gutierrez, M., Doroshow, J. H. & Murgo, A. J. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br. J. Clin. Pharmacol. 62, 15–26 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
• Yap, T. A., Sandhu, S. K., Workman, P. & de Bono, J. S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514–523 (2010).
  Article CAS PubMed Google Scholar
• Attard, G. et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912–2918 (2009).
  Article CAS PubMed Google Scholar
• Petrovics, G. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005).
  Article CAS PubMed Google Scholar
• Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
  Article CAS PubMed Google Scholar
• Attard, G. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253–263 (2008).
  Article CAS PubMed Google Scholar
• Narod, S. A., Seth, A. & Nam, R. Fusion in the ETS gene family and prostate cancer. Br. J. Cancer 99, 847–851 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Bubley, G. J. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 17, 3461–3467 (1999).
  Article CAS PubMed Google Scholar
• Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205–216 (2000).
  Article CAS PubMed Google Scholar
• Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).
  Article PubMed Google Scholar
• Yap, T. A., Sarker, D., Kaye, S. B. & de Bono, J. S in Imaging in Oncology 3rd edn Ch. 61 (eds Husband, J. E. & Reznek, R. H.) 1366–1383 (Informa Healthcare, New York, USA 2010).
  Google Scholar
• Scher, H. I., Warren, M. & Heller, G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin. Cancer Res. 13, 1488–1492 (2007).
  Article CAS PubMed Google Scholar
• de Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302–6309 (2008).
  Article CAS PubMed Google Scholar
• Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268–278 (2008).
  Article CAS PubMed Google Scholar
• D'Amico, A. V. et al. Predictors of mortality after prostate-specific antigen failure. Int. J. Radiat. Oncol. Biol. Phys. 65, 656–660 (2006).
  Article PubMed Google Scholar
• Attard, G. & de Bono, J. S. Prostate cancer: PSA as an intermediate end point in clinical trials. Nat. Rev. Urol. 6, 473–475 (2009).
  Article PubMed Google Scholar
• Attard, G. & de Bono, J. S. Utilizing circulating tumor cells: challenges and pitfalls. Curr. Opin. Genet. Dev. 21, 50–58 (2010).
  Article PubMed CAS Google Scholar
• Defeo, E. M., Wu, C. L., McDougal, W. S. & Cheng, L. L. A decade in prostate cancer: from NMR to metabolomics. Nat. Rev. Urol. 8, 301–311 (2011).
  Article CAS PubMed Google Scholar
• FDA. CellSearch ™ Epithelial Cell Kit/ CellSpotter ™ Analyzer—K031588 [online], (2009).
• Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992–8002 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sternberg, C. N. et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27, 5431–5438 (2009).
  Article CAS PubMed Google Scholar
• Sternberg, C. N. et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol. 20, 1264–1269 (2009).
  Article CAS PubMed Google Scholar
• Sonpavde, G. et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 21, 319–324 (2009).
  Article PubMed Google Scholar
• Cathomas, R. et al. Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07) [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4666 (2010).
  Article Google Scholar
• Small, E. et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer [abstract]. J. Clin. Oncol. 24 (18 Suppl.), a4609 (2006).
  Google Scholar
• Beer, T. M. et al. Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC) [abstract]. J Clin. Oncol. 29 (Suppl.), TPS182 (2011).
  Article Google Scholar
• Drake, C. G. et al. A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D) [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS181 (2011).
  Article Google Scholar
• Tollefson, M. K. et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [abstract]. Genitourinary Cancers Symp. a168 (2010).
• Granberg, C. F. et al. Conversion of advanced prostate cancer to organ-confined minimal residual disease using CTLA-4 blockade (ipilimumab) immunotherapy [abstract]. Genitourinary Cancers Symp. a33 (2010).
• Mohebtash, M. et al. Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a5144 (2009).
  Google Scholar
• Madan, R. A. et al. Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC) [abstract]. Genitourinary Cancers Symp. a38 (2010).
• Fong, L. et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69, 609–615 (2009).
  Article CAS PubMed Google Scholar
• Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Heath, E. I. et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer 4, 138–141 (2005).
  Article CAS PubMed Google Scholar
• Heath, E. I. et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14, 7940–7946 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chi, K. N. et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 4247–4254 (2010).
  Article CAS PubMed Google Scholar
• Chi, K. N. et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7, 3920–3927 (2001).
  CAS PubMed Google Scholar
• Tolcher, A. W. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin. Oncol. 28, 67–70 (2001).
  Article CAS PubMed Google Scholar
• Liu, G. et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 15, 3172–3176 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tolcher, A. W. et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 26, 5198–5203 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Tolcher, A. W. et al. Phase I/II open-label study of YM155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC) [abstract]. Genitourinary Cancers Symp. a214 (2009).
• Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
  Article CAS PubMed Google Scholar
• Sonpavde, G. et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol. Oncol. doi:10.1016/j.urolonc.2009.09.015.
• Sonpavde, G. et al. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin. Genitourin. Cancer 5, 457–459 (2007).
  Article CAS PubMed Google Scholar
• Bradley, D. et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115, 5541–5549 (2009).
  Article CAS PubMed Google Scholar
• Schneider, B. J. et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest. New Drugs doi:10.1007/s10637-010-9503-6.
• Molife, L. R. et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21, 109–113 (2009).
  Article PubMed Google Scholar
• Picus, J. et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 117, 525–533 (2011).
  Article CAS Google Scholar
• Ning, Y. M. et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 2070–2076 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dahut, W. L. et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 14, 209–214 (2008).
  Article CAS PubMed Google Scholar
• Chi, K. N. et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol. 19, 746–751 (2008).
  Article CAS PubMed Google Scholar
• Steinbild, S. et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br. J. Cancer 97, 1480–1485 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Sonpavde, G. et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 21, 319–324 (2010).
  Article CAS PubMed Google Scholar
• Tew, W. P. et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin. Cancer Res. 16, 358–366 (2010).
  Article CAS PubMed Google Scholar
• Adelberg, D. et al. A phase II study of cediranib in post-docetaxel, castration-resistant prostate cancer (CRPC) [abstract]. Genitourinary Cancers Symp. a63 (2010).
• Horti, J. et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother. Radiopharm. 24, 175–180 (2009).
  Article CAS PubMed Google Scholar
• Tiffany, N. M., Wersinger, E. M., Garzotto, M. & Beer, T. M. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 63, 934–939 (2004).
  Article CAS PubMed Google Scholar
• Mathew, P. et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin. Cancer Res. 13, 5816–5824 (2007).
  Article CAS PubMed Google Scholar
• Baselga, J. et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin. Cancer Res. 16, 4876–4883 (2010).
  Article CAS PubMed Google Scholar
• Yu, E. Y. et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77, 1166–1171 (2011).
  Article PubMed Google Scholar
• Armstrong, A. J. et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 14, 6270–6276 (2008).
  Article CAS PubMed Google Scholar
• James, N. D. et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur. Urol. 55, 1112–1123 (2009).
  Article CAS PubMed Google Scholar
• Slovin, S. F. et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin. Genitourin. Cancer 7, E77–E82 (2009).
  Article CAS PubMed Google Scholar
• Boccardo, F. et al. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology 74, 223–228 (2008).
  Article CAS PubMed Google Scholar
• Small, E. J. et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 100, 765–769 (2007).
  Article CAS PubMed Google Scholar
• Canil, C. M. et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 23, 455–460 (2005).
  Article CAS PubMed Google Scholar
• Salzberg, M. et al. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 30, 355–360 (2007).
  CAS PubMed Google Scholar
• Ziada, A. et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60, 332–337 (2004).
  Article CAS PubMed Google Scholar
• Small, E. J., Bok, R., Reese, D. M., Sudilovsky, D. & Frohlich, M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin. Oncol. 28, 71–76 (2001).
  Article CAS PubMed Google Scholar
• Sridhar, S. S. et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am. J. Clin. Oncol. 33, 609–613 (2010).
  Article CAS PubMed Google Scholar
• Dreicer, R. et al. Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest. New Drugs doi:10.1007/s10637-010-9428-0.
• Higano, C. et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC) [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a5142 (2009).
  Google Scholar
• Chi, K. N. et al. A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa) [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4662 (2010).
  Article Google Scholar
• Molife, L. R. et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br. J. Cancer 103, 332–339 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dorff, T. B. et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 16, 3028–3034 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hussain, M. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial [abstract]. J. Clin. Oncol. 29 (Suppl.) a4516 (2011).
  Article Google Scholar
• Yap, T. A. et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 29, 1271–1279 (2011).
  Article CAS PubMed Google Scholar
• Mekhail, T. et al. Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a3548 (2009).
  Google Scholar
• Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217–227 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815–2825 (2006).
  Article CAS PubMed Google Scholar
• Edwards, J., Krishna, N. S., Grigor, K. M. & Bartlett, J. M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89, 552–556 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Brooke, G. N., Parker, M. G. & Bevan, C. L. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27, 2941–2950 (2008).
  Article CAS PubMed Google Scholar
• Hara, T. et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149–153 (2003).
  CAS PubMed Google Scholar
• Elo, J. P. et al. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J. Clin. Endocrinol. Metab. 80, 3494–3500 (1995).
  Article CAS PubMed Google Scholar
• Tan, J. et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 11, 450–459 (1997).
  Article CAS PubMed Google Scholar
• Schweizer, L. et al. The androgen receptor can signal through Wnt/beta-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 9, 4 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Marcelli, M. et al. Androgen receptor mutations in prostate cancer. Cancer Res. 60, 944–949 (2000).
  CAS PubMed Google Scholar
• Taplin, M. E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393–1398 (1995).
  Article CAS PubMed Google Scholar
• Fenton, M. A. et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 3, 1383–1388 (1997).
  CAS PubMed Google Scholar
• Sartor, A. O. et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112, 2393–2400 (2008).
  Article CAS PubMed Google Scholar
• Small, E. J. & Srinivas, S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76, 1428–1434 (1995).
  Article CAS PubMed Google Scholar
• Nadiminty, N. et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 70, 3309–3319 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, H. J. & Lee, W. J. Ligand-independent activation of the androgen receptor by insulin-like growth factor-I and the role of the MAPK pathway in skeletal muscle cells. Mol. Cells 28, 589–593 (2009).
  Article CAS PubMed Google Scholar
• Wegiel, B. et al. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr. Cancer Drug Targets 10, 392–401 (2010).
  Article CAS PubMed Google Scholar
• Mahajan, N. P. et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl Acad. Sci. USA 104, 8438–8443 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, S., Liu, G. Z. & Wang, Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 59, 214–225 (2004).
  Article CAS PubMed Google Scholar
• Whitaker, H. C. & Neal, D. E. RAS pathways in prostate cancer—mediators of hormone resistance? Curr. Cancer Drug Targets 10, 834–839 (2010).
  Article CAS PubMed Google Scholar
• Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575–586 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58–71 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mulholland, D. J. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792–804 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, J. D. et al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell Biochem. 99, 392–401 (2006).
  Article CAS PubMed Google Scholar
• Wen, Y. et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60, 6841–6845 (2000).
  CAS PubMed Google Scholar
• Verras, M. et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67, 967–975 (2007).
  Article CAS PubMed Google Scholar
• Leotoing, L. et al. Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell. Oncogene 27, 2858–2867 (2008).
  Article CAS PubMed Google Scholar
• Desai, S. J., Ma, A. H., Tepper, C. G., Chen, H. W. & Kung, H. J. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res. 66, 10449–10459 (2006).
  Article CAS PubMed Google Scholar
• Comuzzi, B. et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am. J. Pathol. 162, 233–241 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, X. E. et al. Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J. Biol. Chem. 285, 9161–9171 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sadar, M. D. Small molecule inhibitors targeting the “achilles' heel” of androgen receptor activity. Cancer Res 71, 1208–1213 (2011).
  Article CAS PubMed PubMed Central Google Scholar